Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
ConditionObesity and Overweight
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorPfizer
About this trial
This study investigates the efficacy and safety of once weekly injectable MET097 in adult participants with obesity or overweight with weight-related comorbidities excluding T2D. This trial will last for a duration of 84 weeks. The primary endpoint will be assessed after 64 weeks of treatment with the secondary at 84 weeks.
Eligibility criteria
Qualifiers
BMI ≥ 30 kg/m2 or BMI ≥ 27.0 kg/m2 to <30.0 kg/m2 and presence of at least 1 of the following weight- related comorbidities: Hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)
Disqualifiers
Have any form of diabetes
Have a self-reported body weight change > 5 kg (11 pounds) within 3 months prior to Screening
Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
History of chronic pancreatitis or presence of acute pancreatitis within the past 180 days prior to the Screening visit; or active/current, symptomatic gallbladder disease
Trial design
Treatments tested in this trial
- MET097
- Placebo
Treatment groups
3,501 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov